Feed additives for methane mitigation: Modeling the impact of feed additives on enteric methane emission of ruminants-Approaches and recommendations.

Over the past decade, there has been considerable attention on mitigating enteric methane (CH) emissions from ruminants through the utilization of antimethanogenic feed additives (AMFA). Administered in small quantities, these additives demonstrate potential for substantial reductions of methanogenesis. Mathematical models play a crucial role in comprehending and predicting the quantitative impact of AMFA on enteric CH emissions across diverse diets and production systems.

Erratum: First Search for Dyons with the Full MoEDAL Trapping Detector in 13 TeV pp Collisions [Phys. Rev. Lett. 126, 071801 (2021)].

This corrects the article DOI: 10.1103/PhysRevLett.126.

Identifying climate refugia for vulnerable marine ecosystem indicator taxa under future climate change scenarios.

Vulnerable Marine Ecosystems (VMEs) are recognised as having high ecological significance and susceptibility to disturbances, including climate change. One approach to providing information on the location and biological composition of these ecosystems, especially in difficult-to-reach environments such as the deep sea, is to generate spatial predictions for VME indicator taxa. In this study, the Random Forest algorithm was used to model the spatial distribution of density for 14 deep-water VME indicator taxa under current environmental conditions and future climate change scenarios (SSP2-4.

Insomnia Symptoms are Associated with Return to use and Non-fatal Overdose following Opioid Use Disorder Treatment.

Study Objectives: Opioid use disorder (OUD) is a chronic, relapse-prone condition, often accompanied by sleep disturbances such as insomnia. While sleep disturbances have been implicated in negative treatment outcomes, no large-scale studies have examined the relationship between insomnia disorder and outcomes for persons completing an acute OUD treatment episode. This study assessed the association between insomnia symptoms at treatment intake, during treatment, and following acute treatment with post-treatment episode return to use, and non-fatal overdose outcomes.